Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors

(2020) Chiaki Kurimoto et al.   CANCER SCIENCE

Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry

(2020) Rik J. Verheijden et al.   CLINICAL CANCER RESEARCH

Interleukin-23 engineering improves CAR T cell function in solid tumors

(2020) Xingcong Ma et al.   NATURE BIOTECHNOLOGY

Enhanced STAT3 phosphorylation and PD-L1 expression in myeloid dendritic cells indicate impaired IL-27Ralpha signaling in type 1 diabetes

(2020) Z. Parackova et al.   Scientific Reports

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α

(2020) Liku B Tezera et al.   eLife

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2020) Milena Gianfrancesco et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

(2020) Alain P. Algazi et al.   CLINICAL CANCER RESEARCH

Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

(2020) Erica J. Brenner et al.   GASTROENTEROLOGY

High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California

(2020) George Cholankeril et al.   GASTROENTEROLOGY

Kidney disease is associated with in-hospital death of patients with COVID-19

(2020) Yichun Cheng et al.   KIDNEY INTERNATIONAL

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Atul Deodhar et al.   LANCET

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

(2020) Nicole M Kuderer et al.   LANCET

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

(2020) Vikas Mehta et al.   Cancer Discovery

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

(2020) Ling Mao et al.   JAMA Neurology

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database

(2020) Alessandro Ceschi et al.   Frontiers in Pharmacology

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

(2020) Meghan J Mooradian et al.   Journal for ImmunoTherapy of Cancer

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

(2020) Adrienne M. Luoma et al.   CELL

Determinants of COVID-19 disease severity in patients with cancer

(2020) Elizabeth V. Robilotti et al.   NATURE MEDICINE

Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy

(2020) William Murray-Brown et al.   Journal for ImmunoTherapy of Cancer

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

(2020) Andressa S Laino et al.   Journal for ImmunoTherapy of Cancer

Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis

(2020) B.C. Özdemir et al.   ANNALS OF ONCOLOGY

Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

(2020) Yu Zhang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis

(2020) Laura Moi et al.   Journal of Thoracic Oncology

An inflammatory cytokine signature predicts COVID-19 severity and survival

(2020) Diane Marie Del Valle et al.   NATURE MEDICINE

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

(2020) Anne Montfort et al.   CLINICAL CANCER RESEARCH

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

(2020) Jennifer Cautela et al.   Journal for ImmunoTherapy of Cancer

Alteration of specific cytokine expression patterns in patients with breast cancer

(2019) Kosuke Kawaguchi et al.   Scientific Reports

Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

(2019) Susannah L. Hewitt et al.   Science Translational Medicine

Cutting Edge: IL-27 Attenuates Autoimmune Neuroinflammation via Regulatory T Cell/Lag3–Dependent but IL-10–Independent Mechanisms In Vivo

(2019) Dongkyun Kim et al.   JOURNAL OF IMMUNOLOGY

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

(2019) Neal Ready et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

(2019) Devalingam Mahalingam et al.   CLINICAL CANCER RESEARCH

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

(2019) V. Ellen Maher et al.   JOURNAL OF CLINICAL ONCOLOGY

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

(2019) Elisabeth Perez-Ruiz et al.   NATURE

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

(2019) Daniel Johnson et al.   Cancer Immunology Research

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy

(2019) Nikki Burdett et al.   Asia-Pacific Journal of Clinical Oncology

Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab

(2019) Beckey Trinh et al.   DIABETES CARE

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma

(2019) Candice Lesage et al.   JOURNAL OF IMMUNOTHERAPY

Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis

(2019) Paul M Ridker et al.   EUROPEAN HEART JOURNAL

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23

(2019) Maya Kansara et al.   Cancer Discovery

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

(2019) Yousef R. Badran et al.   Journal for ImmunoTherapy of Cancer

Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report

(2019) Alexander Slota et al.   BLOOD

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

(2019) Koji Yoshino et al.   BMC CANCER

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

(2019) Robert J Motzer et al.   LANCET ONCOLOGY

Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage

(2019) Zewen K. Tuong et al.   Scientific Reports

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

(2019) Rebecca A. Gardner et al.   BLOOD

Interleukin-27 Is Essential for Type 1 Diabetes Development and Sjögren Syndrome-like Inflammation

(2019) Ashley E. Ciecko et al.   Cell Reports

Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses

(2019) Samantha K. Greaney et al.   Cancer Immunology Research

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

(2018) Florentia Dimitriou et al.   JOURNAL OF IMMUNOTHERAPY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

(2018) Laura C. Cappelli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

(2018) Yinghong Wang et al.   Journal for ImmunoTherapy of Cancer

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

(2018) Arianna Calcinotto et al.   NATURE

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

(2018) Norio Chihara et al.   NATURE

Immune dysregulation in cancer patients developing immune-related adverse events

(2018) Shaheen Khan et al.   BRITISH JOURNAL OF CANCER

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

(2018) Su Y. Lim et al.   CLINICAL CANCER RESEARCH

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation

(2018) Irena Kaplanov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

(2018) Arabella Young et al.   Cancer Immunology Research

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series

(2018) Kendall F. Moseley et al.   Journal for ImmunoTherapy of Cancer

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy

(2018) Alice Horisberger et al.   Journal for ImmunoTherapy of Cancer

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

(2018) Daniel H Johnson et al.   Journal for ImmunoTherapy of Cancer

Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis

(2017) Cindy Franklin et al.   EUROPEAN JOURNAL OF CANCER

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity

(2017) Ryota Tanaka et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Is autoimmunity the Achilles' heel of cancer immunotherapy?

(2017) Carl H June et al.   NATURE MEDICINE

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

(2017) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy

(2017) Seth J. Rotz et al.   PEDIATRIC BLOOD & CANCER

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

(2017) Florie Bertrand et al.   Nature Communications

Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials

(2017) Zheng Zhang et al.   BMJ Open

Reciprocal Expression of IL-35 and IL-10 Defines Two Distinct Effector Treg Subsets that Are Required for Maintenance of Immune Tolerance

(2017) Xundong Wei et al.   Cell Reports

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.

(2017) M. K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

(2016) Jing Liu et al.   CANCER RESEARCH

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor

(2016) Shin Foong Ngiow et al.   CANCER RESEARCH

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

(2016) M. Nishino et al.   CLINICAL CANCER RESEARCH

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

(2016) Maria Del Castillo et al.   CLINICAL INFECTIOUS DISEASES

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

(2016) Marc Uemura et al.   Journal of Hematology & Oncology

Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice

(2016) Tze Guan Tan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ipilimumab-induced colitis: experience from a tertiary referral center

(2016) Anthony O’Connor et al.   Therapeutic Advances in Gastroenterology

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis

(2016) Katharina Lankes et al.   OncoImmunology

Infliximab for IPILIMUMAB-Related Colitis--Letter

(2015) E. Arriola et al.   CLINICAL CANCER RESEARCH

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytokines in rheumatoid arthritis — shaping the immunological landscape

(2015) Iain B. McInnes et al.   Nature Reviews Rheumatology

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction

(2015) Chen Zhu et al.   Nature Communications

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

(2014) G. L. Stritesky et al.   JOURNAL OF IMMUNOLOGY

IL-27 in tumor immunity and immunotherapy

(2013) Gopal Murugaiyan et al.   TRENDS IN MOLECULAR MEDICINE

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

IL-17 Enhances Tumor Development in Carcinogen-Induced Skin Cancer

(2010) L. Wang et al.   CANCER RESEARCH

Cutting Edge: CTLA-4-B7 Interaction Suppresses Th17 Cell Differentiation

(2010) H. Ying et al.   JOURNAL OF IMMUNOLOGY

Endogenous IL-17 contributes to reduced tumor growth and metastasis

(2009) I. Kryczek et al.   BLOOD

T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

(2009) Natalia Martin-Orozco et al.   IMMUNITY

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine